Ryan J. Rebernick
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ryan J. Rebernick has a total of 156 co-authors. Here are the top co-authors by number of shared publications:
- Marcin P. Cieslik
Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan
72 shared publications - Abel González-Pérez
Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Baldiri Reixac, 10, 08028 Barcelona, Spain
48 shared publications - Alexander William Wyatt
Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, Canada
48 shared publications - Anna Oliveira Tercero
10Department of Medical Oncology and Prostate Cancer Translational Research Group, Vall d’Hebron Institute of Oncology (VHIO) and Vall d’Hebron University Hospital, Barcelona, Spain
48 shared publications - Aslı D. Munzur
Vancouver Prostate Centre Department of Urologic Sciences University of British Columbia British Columbia Canada
48 shared publications - Chen Weller
Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel
48 shared publications
Latest Publications
- Open Access
- 20 October 2026
- Published by Springer Nature in Nature Communications
Fatty acids in the tumor microenvironment reprogram neutrophils to induce adenosine-mediated immunosuppression in mice
- 20 October 2026
- Published by Springer Nature in Nature Communications
Open AccessFatty acids in the tumor microenvironment reprogram neutrophils to induce adenosine-mediated immunosuppression in mice
- Open Access
Genomic Determinants of Lethality and Therapeutic Vulnerability in Castration-Resistant Prostate Cancer
SUMMARY: Despite extensive characterization, the molecular determinants that shape disease progression and therapeutic outcomes in metastatic castration-resistant prostate cancer (mCRPC) remain incompletely defined. This large, multi-institutional analysis reveals that the genomic determinants of outcomes in primary prostate cancer are distinct from those in castration-resistant disease. We identify androgen-regulated MYC fusions as potent primary genetic drivers catalyzing early progression. Additionally, across independent mCRPC cohorts, we validate TP53, RB1 , and CDKN1B alterations as the strongest genetic drivers of poor survival. Mechanistically, CDKN1B loss induces an AR-positive epithelial–mesenchymal transition rather than neuroendocrine differentiation, while TP53 loss triggers whole-genome duplication and subsequent adaptive copy-number gains. Within TP53-altered tumors, AR amplifications confer improved survival while AR mutations are protective regardless of TP53 status. Integrating these genomic events with transcriptomic phenotypes, we derive CAPrisk, a multi-omic prognostic classifier. CAPrisk stratifies patients with mCRPC into three risk groups with >33-month survival differences and predicts outcomes across androgen receptor pathway inhibitors, taxanes, PARP-inhibitors, and radium-223. Together, these findings expand the clinical utility of genomic profiling in advanced prostate cancer and establish a framework for risk stratification in lethal disease. IN BRIEF (eTOC BLURB): Rebernick et al. analyze a multi-institutional cohort of 1,331 prostate cancer samples and identify the genomic determinants of progression to lethal, castration-resistant disease. They define rare AR-regulated MYC fusions and haploinsufficient CDKN1B loss as drivers of poor outcome while highlighting AR alterations as predictors of improved prognosis. They develop CAPrisk, a multi-omic classifier that stratifies patient outcomes across androgen receptor pathway inhibitors, taxanes, PARP-inhibitors, and radium-223. HIGHLIGHTS: – AR-regulated MYC fusions are rare (∼2%) truncal events driving aggressive disease. – Distinct AR alterations drive favorable outcomes in TP53 -altered and non-altered contexts. – Haploinsufficient CDKN1B loss predicts poor survival in AR-positive tumors. – A multi-omic model predicts outcomes across four standard-of-care therapies. MI-OncoSeq Team: Chandan Kumar, Erica Rabban, Kayla Muschong, Lakshmi P. Kunju, Javed Siddiqui, Yu Ning, Rui Wang, Fengyun Su, Yelena Kleyman-Smith, Josh N. Vo, Jin Chen, Rahul Mannan Stand Up To Cancer Team: Wassim Abida, Joanna Cyrta, Glenn Heller, Davide Prandi, Joshua Armenia, Ilsa Coleman, Matteo Benelli, Eliezer M. Van Allen, Andrea Sboner, Tarcisio Fedrizzi, Juan Miguel Mosquera, Brian D. Robinson, Navonil De Sarkar, Lakshmi P. Kunju, Scott Tomlins, Daniel Nava Rodrigues, Massimo Loda, Anuradha Gopalan, Victor E. Reuter, Colin C. Pritchard, Joaquin Mateo, Diletta Bianchini, Susana Miranda, Suzanne Carreira, Pasquale Rescigno, Julie Filipenko, Jacob Vinson, Robert B. Montgomery, Himisha Beltran, Elisabeth I. Heath, Howard I. Scher, Philip W. Kantoff, Mary-Ellen Taplin, Nikolaus Schultz, Johann S. deBono, Francesca Demichelis, Peter S. Nelson, Mark A. Rubin, Charles Sawyers
Open AccessGenomic Determinants of Lethality and Therapeutic Vulnerability in Castration-Resistant Prostate Cancer
SUMMARY: Despite extensive characterization, the molecular determinants that shape disease progression and therapeutic outcomes in metastatic castration-resistant prostate cancer (mCRPC) remain incompletely defined. This large, multi-institutional analysis reveals that the genomic determinants of outcomes in primary prostate cancer are distinct from those in castration-resistant disease. We identify androgen-regulated MYC fusions as potent primary genetic drivers catalyzing early progression. Additionally, across independent mCRPC cohorts, we validate TP53, RB1 , and CDKN1B alterations as the strongest genetic drivers of poor survival. Mechanistically, CDKN1B loss induces an AR-positive epithelial–mesenchymal transition rather than neuroendocrine differentiation, while TP53 loss triggers whole-genome duplication and subsequent adaptive copy-number gains. Within TP53-altered tumors, AR amplifications confer improved survival while AR mutations are protective regardless of TP53 status. Integrating these genomic events with transcriptomic phenotypes, we derive CAPrisk, a multi-omic prognostic classifier. CAPrisk stratifies patients with mCRPC into three risk groups with >33-month survival differences and predicts outcomes across androgen receptor pathway inhibitors, taxanes, PARP-inhibitors, and radium-223. Together, these findings expand the clinical utility of genomic profiling in advanced prostate cancer and establish a framework for risk stratification in lethal disease. IN BRIEF (eTOC BLURB): Rebernick et al. analyze a multi-institutional cohort of 1,331 prostate cancer samples and identify the genomic determinants of progression to lethal, castration-resistant disease. They define rare AR-regulated MYC fusions and haploinsufficient CDKN1B loss as drivers of poor outcome while highlighting AR alterations as predictors of improved prognosis. They develop CAPrisk, a multi-omic classifier that stratifies patient outcomes across androgen receptor pathway inhibitors, taxanes, PARP-inhibitors, and radium-223. HIGHLIGHTS: – AR-regulated MYC fusions are rare (∼2%) truncal events driving aggressive disease. – Distinct AR alterations drive favorable outcomes in TP53 -altered and non-altered contexts. – Haploinsufficient CDKN1B loss predicts poor survival in AR-positive tumors. – A multi-omic model predicts outcomes across four standard-of-care therapies. MI-OncoSeq Team: Chandan Kumar, Erica Rabban, Kayla Muschong, Lakshmi P. Kunju, Javed Siddiqui, Yu Ning, Rui Wang, Fengyun Su, Yelena Kleyman-Smith, Josh N. Vo, Jin Chen, Rahul Mannan Stand Up To Cancer Team: Wassim Abida, Joanna Cyrta, Glenn Heller, Davide Prandi, Joshua Armenia, Ilsa Coleman, Matteo Benelli, Eliezer M. Van Allen, Andrea Sboner, Tarcisio Fedrizzi, Juan Miguel Mosquera, Brian D. Robinson, Navonil De Sarkar, Lakshmi P. Kunju, Scott Tomlins, Daniel Nava Rodrigues, Massimo Loda, Anuradha Gopalan, Victor E. Reuter, Colin C. Pritchard, Joaquin Mateo, Diletta Bianchini, Susana Miranda, Suzanne Carreira, Pasquale Rescigno, Julie Filipenko, Jacob Vinson, Robert B. Montgomery, Himisha Beltran, Elisabeth I. Heath, Howard I. Scher, Philip W. Kantoff, Mary-Ellen Taplin, Nikolaus Schultz, Johann S. deBono, Francesca Demichelis, Peter S. Nelson, Mark A. Rubin, Charles Sawyers
- Open Access
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Recurrent Immunogenic Neoantigens and Their Cognate T-cell Receptors in Treatment-Resistant Metastatic Prostate Cancer
Immunogenicity and cross reactivity of CD8+ T transduced with specific AR H875Y TCRs
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Recurrent Immunogenic Neoantigens and Their Cognate T-cell Receptors in Treatment-Resistant Metastatic Prostate Cancer
Immunogenicity and cross reactivity of CD8+ T transduced with specific AR H875Y TCRs
- Open Access
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S8 from Recurrent Immunogenic Neoantigens and Their Cognate T-cell Receptors in Treatment-Resistant Metastatic Prostate Cancer
Single Cell TCRseq of donor 157 with AR H875Y 9-mer dextramer staining sorted T-cells
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S8 from Recurrent Immunogenic Neoantigens and Their Cognate T-cell Receptors in Treatment-Resistant Metastatic Prostate Cancer
Single Cell TCRseq of donor 157 with AR H875Y 9-mer dextramer staining sorted T-cells
- Open Access
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Recurrent Immunogenic Neoantigens and Their Cognate T-cell Receptors in Treatment-Resistant Metastatic Prostate Cancer
HLA-B*15:01 Binding Predictions for AR H875Y by NetMHCpan 8 to 14 flanking the mutation
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Recurrent Immunogenic Neoantigens and Their Cognate T-cell Receptors in Treatment-Resistant Metastatic Prostate Cancer
HLA-B*15:01 Binding Predictions for AR H875Y by NetMHCpan 8 to 14 flanking the mutation
- Open Access
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S16 from Recurrent Immunogenic Neoantigens and Their Cognate T-cell Receptors in Treatment-Resistant Metastatic Prostate Cancer
Synthetic peptides used in this study
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S16 from Recurrent Immunogenic Neoantigens and Their Cognate T-cell Receptors in Treatment-Resistant Metastatic Prostate Cancer
Synthetic peptides used in this study
- Open Access
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Recurrent Immunogenic Neoantigens and Their Cognate T-cell Receptors in Treatment-Resistant Metastatic Prostate Cancer
Specific AR H875Y T157.2 TCR reactivity in healthy donor PBMCs
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Recurrent Immunogenic Neoantigens and Their Cognate T-cell Receptors in Treatment-Resistant Metastatic Prostate Cancer
Specific AR H875Y T157.2 TCR reactivity in healthy donor PBMCs
- Open Access
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from Recurrent Immunogenic Neoantigens and Their Cognate T-cell Receptors in Treatment-Resistant Metastatic Prostate Cancer
Specific AR H875Y TCR cytotoxicity in healthy donor PBMCs
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from Recurrent Immunogenic Neoantigens and Their Cognate T-cell Receptors in Treatment-Resistant Metastatic Prostate Cancer
Specific AR H875Y TCR cytotoxicity in healthy donor PBMCs
- Open Access
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Recurrent Immunogenic Neoantigens and Their Cognate T-cell Receptors in Treatment-Resistant Metastatic Prostate Cancer
HLA-A*01:01 Binding Predictions for AR H875Y by NetMHCpan 8 to 14 flanking the mutation
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Recurrent Immunogenic Neoantigens and Their Cognate T-cell Receptors in Treatment-Resistant Metastatic Prostate Cancer
HLA-A*01:01 Binding Predictions for AR H875Y by NetMHCpan 8 to 14 flanking the mutation
- Open Access
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S13 from Recurrent Immunogenic Neoantigens and Their Cognate T-cell Receptors in Treatment-Resistant Metastatic Prostate Cancer
Distribution of cancer types and metastatic locations in the Hartwig cohort
- 9 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S13 from Recurrent Immunogenic Neoantigens and Their Cognate T-cell Receptors in Treatment-Resistant Metastatic Prostate Cancer
Distribution of cancer types and metastatic locations in the Hartwig cohort